全文获取类型
收费全文 | 2094696篇 |
免费 | 158633篇 |
国内免费 | 10293篇 |
专业分类
耳鼻咽喉 | 29837篇 |
儿科学 | 68395篇 |
妇产科学 | 58248篇 |
基础医学 | 293077篇 |
口腔科学 | 56413篇 |
临床医学 | 186128篇 |
内科学 | 412814篇 |
皮肤病学 | 43977篇 |
神经病学 | 161952篇 |
特种医学 | 82561篇 |
外国民族医学 | 979篇 |
外科学 | 317618篇 |
综合类 | 62033篇 |
现状与发展 | 21篇 |
一般理论 | 606篇 |
预防医学 | 157002篇 |
眼科学 | 47872篇 |
药学 | 157989篇 |
116篇 | |
中国医学 | 10318篇 |
肿瘤学 | 115666篇 |
出版年
2021年 | 17976篇 |
2019年 | 17630篇 |
2018年 | 23790篇 |
2017年 | 18971篇 |
2016年 | 19948篇 |
2015年 | 24092篇 |
2014年 | 33263篇 |
2013年 | 47868篇 |
2012年 | 65826篇 |
2011年 | 69956篇 |
2010年 | 43065篇 |
2009年 | 40035篇 |
2008年 | 64417篇 |
2007年 | 68303篇 |
2006年 | 68176篇 |
2005年 | 66293篇 |
2004年 | 62592篇 |
2003年 | 60398篇 |
2002年 | 58636篇 |
2001年 | 95733篇 |
2000年 | 98759篇 |
1999年 | 84285篇 |
1998年 | 23863篇 |
1997年 | 21773篇 |
1996年 | 21800篇 |
1995年 | 20539篇 |
1994年 | 19494篇 |
1993年 | 17881篇 |
1992年 | 65453篇 |
1991年 | 63822篇 |
1990年 | 62122篇 |
1989年 | 59250篇 |
1988年 | 54748篇 |
1987年 | 53900篇 |
1986年 | 50630篇 |
1985年 | 48546篇 |
1984年 | 36335篇 |
1983年 | 30772篇 |
1982年 | 18224篇 |
1979年 | 33025篇 |
1978年 | 23034篇 |
1977年 | 19469篇 |
1976年 | 18341篇 |
1975年 | 19939篇 |
1974年 | 23636篇 |
1973年 | 22705篇 |
1972年 | 21162篇 |
1971年 | 19278篇 |
1970年 | 18423篇 |
1969年 | 16875篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
2.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
3.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
4.
5.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
6.
7.
8.
9.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.